OBJECTIVE: To determine the conversion risk and predictors for depression in women with polycystic ovary syndrome. DESIGN: Prospective longitudinal study. SETTING: University practice. PATIENT(S): Subjects with polycystic ovary syndrome who had participated in a previous study. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): The Primary Care Evaluation of Mental Disorders Patient Health Questionnaire was used to diagnose major depressive disorder and other depressive syndromes, anxiety syndromes, and binge eating disorder. Subjects completed a questionnaire on knowledge about polycystic ovary syndrome and treatment satisfaction. RESULT(S): A total of 60 of 103 subjects responded to the second survey. Mean time between the two surveys was 22 months (range 12-26 months). The overall prevalence of depression was 40% (24/60). Of these, 10 women screened positive for major depressive disorder or other depressive syndromes and 14 were receiving antidepressant medications. There were 11 new cases identified in the second survey (19% conversion). Total subjects with mood disorders in this study were 34/60 (56.6%), including 11.6% with anxiety syndromes and 23.3% with binge eating disorder. Difficulties with menstrual function, fertility, and body image (weight, hirsutism, acne) were not significantly different in women with and without depression. CONCLUSION(S): There is a significant risk for mood disorders (defined by the Diagnostic and Statistical Manual of Mental Disorders-IV) in women with polycystic ovary syndrome. This finding together with a high conversion risk for depression over a 1- to 2-year period underscores the importance of routine screening and aggressive treatment of mental health disorders in this population.
OBJECTIVE: To determine the conversion risk and predictors for depression in women with polycystic ovary syndrome. DESIGN: Prospective longitudinal study. SETTING: University practice. PATIENT(S): Subjects with polycystic ovary syndrome who had participated in a previous study. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): The Primary Care Evaluation of Mental DisordersPatient Health Questionnaire was used to diagnose major depressive disorder and other depressive syndromes, anxiety syndromes, and binge eating disorder. Subjects completed a questionnaire on knowledge about polycystic ovary syndrome and treatment satisfaction. RESULT(S): A total of 60 of 103 subjects responded to the second survey. Mean time between the two surveys was 22 months (range 12-26 months). The overall prevalence of depression was 40% (24/60). Of these, 10 women screened positive for major depressive disorder or other depressive syndromes and 14 were receiving antidepressant medications. There were 11 new cases identified in the second survey (19% conversion). Total subjects with mood disorders in this study were 34/60 (56.6%), including 11.6% with anxiety syndromes and 23.3% with binge eating disorder. Difficulties with menstrual function, fertility, and body image (weight, hirsutism, acne) were not significantly different in women with and without depression. CONCLUSION(S): There is a significant risk for mood disorders (defined by the Diagnostic and Statistical Manual of Mental Disorders-IV) in women with polycystic ovary syndrome. This finding together with a high conversion risk for depression over a 1- to 2-year period underscores the importance of routine screening and aggressive treatment of mental health disorders in this population.
Authors: Penina Segall-Gutierrez; Courtney S Berman; Neisha Opper; Emily Dossett; Kimberly Moore; Courtney Martin; Janet Pine Journal: J Immigr Minor Health Date: 2012-12
Authors: Iris Lee; Laura G Cooney; Shailly Saini; Mary D Sammel; Kelly C Allison; Anuja Dokras Journal: Eat Weight Disord Date: 2018-06-26 Impact factor: 4.652
Authors: Judy G McCook; Beth A Bailey; Stacey L Williams; Sheeba Anand; Nancy E Reame Journal: J Behav Health Serv Res Date: 2015-07 Impact factor: 1.505
Authors: Monica Algars; Lu Huang; Ann F Von Holle; Christine M Peat; Laura M Thornton; Paul Lichtenstein; Cynthia M Bulik Journal: J Psychosom Res Date: 2013-11-28 Impact factor: 3.006